SLC5A2 and type 2 diabetes mellitus: Large scale trials (EMPA-REG OUTCOME, CANVAS, and CANVAS-R) established the safety of SGLT2 inhibitors and have demonstrated a reduction in the frequency of cardiovascular events and risk of renal failure in patients with type 2 diabetes mellitus (T2DM), with an elevated risk of cardiovascular disease and an increased risk of amputation [6–8].